Nonsustained ventricular tachycardia (VT) occurs frequently in patients hospitalized with acute coronary syndromes, although the clinical implications of VT remain uncertain, in particular relative to the absolute risk of sudden cardiac death in patients with shorter episodes of ventricular ectopy and the relationship between the timing of VT after hospital admission and prognosis. In this study of Ͼ6300 patients admitted with non-ST-elevation acute coronary syndrome and enrolled in the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial who had 7-day continuous ECG monitoring, we found a Ͼ2-fold increase in the risk of sudden cardiac death in patients with both short (4 to 7 beats in length) and longer (Ն8 beats in length) episodes of VT compared with patients with no VT. This relationship was unchanged after adjustment for clinical characteristics, including left ventricular ejection fraction and natriuretic peptides. In contrast, there was no increased risk of sudden cardiac death in patients with ventricular triplets. In regard to timing of VT, we found that only episodes occurring Ͼ48 hours after admission were associated with an increased risk of sudden cardiac death, whereas earlier episodes within 48 hours did not carry the same risk. In several subgroups (history of heart failure, depressed ventricular function, QTc Ͼ450 milliseconds), the presence of VT was associated with a Ͼ10% incidence of sudden cardiac death at 1 year. The results of our study suggest that the use of extended continuous ECG monitoring beyond 48 hours after admission for non-ST-elevation acute coronary syndrome to detect the presence of even short episodes of VT may potentially identify patients at higher risk for sudden death. See p 455.
Prognostic Value of Lead V 1 ST Elevation During Acute Inferior Myocardial Infarction
The standard 12-lead ECG is a cornerstone in the diagnosis and stratification of patients with ST-elevation acute myocardial infarction. Concomitant right ventricular infarction (often manifested with V 1 ST elevation) or posterolateral infarction (often manifested with V 3 ST depression) can be associated with worse prognosis of patients with acute inferior myocardial infarction. In this study of 7967 patients with acute inferior myocardial infarction from the Hirulog and Early Reperfusion or Occlusion-2 (HERO-2) trial, ST elevation in V 1 at baseline had incremental adverse prognostic significance that was independent of the adverse effect of any precordial V 3 ST depression. Thirty-day mortality increased with increasing V 1 ST elevation (5.2% with 0 mm, 6.4% with 0.5 mm, 6.8% with 1 mm, and 10.3% with Ն1.5 mm; P for trend Ͻ0.0001). Each 0.5-mm-step increase in ST level above the isoelectric level was associated with Ϸ25% increase in 30-day mortality before and after adjustments. V 1 ST elevation Ն1 mm, analyzed dichotomously in all patients, was associated with higher mortality. The odds ratio was 1.28 (95% confidence interval, 1.01 to 1.61) unadjusted, 1.51 (95% confidence interval, 1.18 to 1.92) adjusted for V 3 ST level, and 1.35 (95% confidence interval, 1.04 to 1.76) adjusted for ECG and clinical factors. Resolution of V 1 ST elevation after fibrinolytic therapy was associated with lowered 30-day mortality (5.5% versus 10.8%; Pϭ0.0012), lending further support to the independent prognostic value of this simple ECG parameter. Standard 12-lead ECGs are increasingly being performed before hospitalization to enable shorter times to fibrinolysis or to percutaneous coronary intervention. This study supports use of information from readily available V 1 recordings in aiding risk stratification and prognostication. See p 463.
Genetic Variation at the Phospholipid Transfer Protein Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility
Whether modulation of high-density lipoprotein (HDL) metabolism will result in atheroprotection is one of the great conundrums of vascular medicine. Phospholipid transfer protein (PLTP) is a key player in HDL metabolism. The present study demonstrates a robust association between genetic variation in the PLTP gene, expression of PLTP in the liver, concentration and activity of PLTP in plasma, and cardiovascular disease risk, strengthening the concept that the actions of PLTP are proatherogenic in nature. Of note, PLTP genotype was not associated with HDL cholesterol concentrations but with HDL size distribution; apparently, PLTP action results in fewer but larger HDL particles. Together, these findings are consistent with the idea that specific elements of HDL metabolism may indeed affect cardiovascular risk but without necessarily affecting HDL cholesterol levels. More specifically, our observations suggest that the inhibition of PLTP may be an attractive strategy to reduce cardiovascular disease risk. See p 470.
Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension
Preeclampsia, defined by the gestational onset of hypertension and proteinuria, affects 2% to 4% of first-time pregnancies and accounts for 15% to 25% of all maternal deaths in the United States and Europe. Delivery is the only cure but carries the risk of neonatal morbidity and mortality in cases of preterm preeclampsia. Understanding the pathogenesis of preeclampsia is necessary to improve outcomes. It has been proposed that rises in maternal serum levels of 2 antiangiogenic factors, soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin, and a reduction in placental growth factor contribute to maternal endothelial dysfunction and consequently preeclampsia. In this study, we prospectively evaluated the relationship between these factors and found that women who develop preterm preeclampsia have an attenuated rise in placental growth factor and excessive soluble endoglin, followed by an exaggerated rise in sFlt-1. The relationships between these biomarkers and maternal blood pressure strengthen as pregnancy progresses and at 23 to 25 weeks extend to a correlation with raised uterine artery resistance, a recognized precursor of preterm preeclampsia. Women who start pregnancy with an elevated blood pressure develop preeclampsia at lower circulating levels of sFlt-1, further supporting a pathogenic role for sFlt-1 through resistance vessel dysfunction. Gestational hypertension develops differently from preeclampsia, with a hyperdynamic circulation and angiogenic biomarker profile similar to normotensive pregnancy. sFlt-1, soluble endoglin, and
